Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

Hdl Handle:
http://hdl.handle.net/10144/619030
Title:
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
Authors:
Achar, J; Hewison, C; Cavalheiro, AP; Skrahina, A; Cajazeiro, J; Nargiza, P; Herboczek, K; Rajabov, A; Hughes, J; Ferlazzo, G; Seddon, JA; du Cros, P
Journal:
Emerging Infectious Diseases
Abstract:
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Publisher:
Centers for Disease Control and Prevention
Issue Date:
Oct-2017
URI:
http://hdl.handle.net/10144/619030
DOI:
10.3201/eid2310.170303
PubMed ID:
28758889
Submitted date:
2017-10-18
Language:
en
ISSN:
1080-6059
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorAchar, Jen
dc.contributor.authorHewison, Cen
dc.contributor.authorCavalheiro, APen
dc.contributor.authorSkrahina, Aen
dc.contributor.authorCajazeiro, Jen
dc.contributor.authorNargiza, Pen
dc.contributor.authorHerboczek, Ken
dc.contributor.authorRajabov, Aen
dc.contributor.authorHughes, Jen
dc.contributor.authorFerlazzo, Gen
dc.contributor.authorSeddon, JAen
dc.contributor.authordu Cros, Pen
dc.date.accessioned2017-10-24T14:02:29Z-
dc.date.available2017-10-24T14:02:29Z-
dc.date.issued2017-10-
dc.date.submitted2017-10-18-
dc.identifier.citationOff-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. 2017, 23 (10) Emerging Infect. Dis.en
dc.identifier.issn1080-6059-
dc.identifier.pmid28758889-
dc.identifier.doi10.3201/eid2310.170303-
dc.identifier.urihttp://hdl.handle.net/10144/619030-
dc.description.abstractWe describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.en
dc.language.isoenen
dc.publisherCenters for Disease Control and Preventionen
dc.rightsPublished by Centers for Disease Control (CDC) Archived on this site by permission of CDC, [url]http://www.cdc.gov/ncidod/eid[/url]en
dc.titleOff-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosisen
dc.identifier.journalEmerging Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.